The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice
Open accessAbstract
Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor that controls expression of genes involved in lipid metabolism and is activated by fatty acids and hypolipidaemic fibrates. Fibrates induce the hepatic expression of murine multidrug resistance 2 (Mdr2), encoding the canalicular phospholipid translocator. The physiological role of PPARα in regulation of Mdr2 and other genes involved in bile formation is unknown. We found no differences in hepatic expression of the ATP binding cassette transporter genes Mdr2, Bsep (bile salt export pump), Mdr1a/1b, Abca1 and Abcg5/Abcg8 (implicated in cholesterol transport), the bile salt-uptake systems Ntcp (Na+-taurocholate co-transporting polypeptide gene) and Oatp1 (organic anion-transporting polypeptide 1 gene) or in bile formation between wild-type and Pparα(-/-) mice. Upon treatment of wild-type mice with ciprofibrate (0.05%, w/w, in diet for 2 weeks), the expression of Mdr2 (+3-fold), Mdr1a (+6-fold) and Mdr1b (+11-fold) mRNAs was clearly induced, while that of Oatp1 (-5-fold) was reduced. Mdr2 protein levels were increased, whereas Bsep, Ntcp and Oatp1 were drastically decreased. Exposure of cultured wild-type mouse hepatocytes to PPARα agonists specifically induced Mdr2 mRNA levels and did not affect expression of Mdr1a/1b. Altered transporter expression in fibrate-treated wild-type mice was associated with a 400% increase in bile flow: secretion of phospholipids and cholesterol was increased only during high-bile-salt infusions. No fibrate effects were observed in Pparα(-/-) mice. In conclusion, our results show that basal bile formation is not affected by PPARα deficiency in mice. The induction of Mdr2 mRNA and Mdr2 protein levels by fibrates is mediated by PPARα, while the induction of Mdr1a/1b in vivo probably reflects a secondary phenomenon related to chronic PPARα activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Self-citationKast, H. R., Goodwin, B., Tarr, P. T., Jones, S. A., Anisfeld, A. M., Stoltz, C. M., Tontonoz, P., Kliewer, S., Willson, T. M., & Edwards, P. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109326200 · Cited by 916
Edgar, A. D., Tomkiewicz, C., Costet, P., Legendre, C., Aggerbeck, M., Bouguet, J., Staels, B., Guyomard, C., Pineau, T., & Barouki, R. (1998) · Toxicology Letters · doi:10.1016/s0378-4274(98)00042-3 · Cited by 71
Self-citation
Cited by
Khovidhunkit, W., Kim, M.-S., Memon, R. A., Shigenaga, J. K., Moser, A. H., Feingold, K. R., & Grunfeld, C. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r300019-jlr200 · Cited by 1,481
“increases BSEP expression (230), FXR, PXR, and CAR activation increase MRP2 expression (231), LXR activation increases ABCG5 and ABCG8 expression (232), and PPAR-± activation increases MDR2 expression (233).”
Peroxisome Proliferator-Activated Receptor Alpha Target Genes
Rakhshandehroo, M., Knoch, B., Müller, M., & Kersten, S. (2010) · PPAR Research · doi:10.1155/2010/612089 · Cited by 1,020
Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation
Klaassen, C. D., & Aleksunes, L. M. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002014 · Cited by 807
Enterohepatic bile salt transporters in normal physiology and liver disease
Kullak-ublick, G. A., Stieger, B., & Meier, P. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.06.005 · Cited by 658
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537
“For the application of PPAR agonists in cholestatic liver disease the notion that the canalicular phospholipid translocator MDR3 is a PPARa responsive gene is relevant [152,153].”
BackgroundSelf-citationWagner, M., Halilbasic, E., Marschall, H., Zollner, G., Fickert, P., Langner, C., Zatloukal, K., Denk, H., & Trauner, M. (2005) · Hepatology · doi:10.1002/hep.20784 · Cited by 355
Ghonem, N. S., Assis, D. N., & Boyer, J. L. (2015) · Hepatology · doi:10.1002/hep.27744 · Cited by 317
“For example, ciprofibrate and Wy-14,643 treatment up-regulate Mdr2 mRNA expression in primary hepatocytes and liver tissue of WT, but not Pparanull, mice, yet WT mice displayed an increase in bile flow in spite of reduced biliary phospholipid and bile salt concentrations.(39) Others(40) reported that a 0.”
BackgroundGeier, A., Wagner, M., Dietrich, C. G., & Trauner, M. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.04.014 · Cited by 314
Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein)
Oude Elferink, R. P. J., & Paulusma, C. C. (2007) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-006-0062-9 · Cited by 282
The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts
Chandra, P., & Brouwer, K. L. R. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000026420.79421.8f · Cited by 266
New molecular insights into the mechanisms of cholestasis
Wagner, M., Zollner, G., & Trauner, M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.012 · Cited by 260
PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
Hong, F., Pan, S., Guo, Y., Xu, P., & Zhai, Y. (2019) · Molecules · doi:10.3390/molecules24142545 · Cited by 233
“Hepatic Na+-taurocholate cotransporting polypeptide (NTCP), organic-anion-transporting polypeptide (OATP1), and bile salt export pump (BSEP) are involved in the regulation of bile acid influx in the liver by activating PPARα, and this phenotype is abolished in PPARα-null mice [53].”
BackgroundHonda, A., Ikegami, T., Nakamuta, M., Miyazaki, T., Iwamoto, J., Hirayama, T., Saito, Y., Takikawa, H., Imawari, M., & Matsuzaki, Y. (2013) · Hepatology · doi:10.1002/hep.26018 · Cited by 210
DUVAL, C., MULLER, M., & KERSTEN, S. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.05.003 · Cited by 199
Nuclear receptors as therapeutic targets in cholestatic liver diseases
Zollner, G., & Trauner, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00030.x · Cited by 146
Hosonuma, K., Sato, K., Yamazaki, Y., Yanagisawa, M., Hashizume, H., Horiguchi, N., Kakizaki, S., Kusano, M., & Yamada, M. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.20 · Cited by 123
Savolainen, K., Kotti, T. J., Schmitz, W., Savolainen, T. I., Sormunen, R. T., Ilves, M., Vainio, S. J., Conzelmann, E., & Hiltunen, J. K. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh107 · Cited by 83
More, V. R., Campos, C. R., Evans, R. A., Oliver, K. D., Chan, G. N., Miller, D. S., & Cannon, R. E. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16650216 · Cited by 59
Shoda, J., Inada, Y., Tsuji, A., Kusama, H., Ueda, T., Ikegami, T., Suzuki, H., Sugiyama, Y., Cohen, D. E., & Tanaka, N. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400132-jlr200 · Cited by 58
Ghonem, N. S., Auclair, A. M., Hemme, C. L., Gallucci, G. M., de la Rosa Rodriguez, R., Boyer, J. L., & Assis, D. N. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1930 · Cited by 57
Akanuma, S.-I., Hori, S., Ohtsuki, S., Fujiyoshi, M., & Terasaki, T. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2007.08.012 · Cited by 43
Sugiyama, E., Ishikawa, Y., Li, Y., Kagai, T., Nobayashi, M., Tanaka, N., Kamijo, Y., Yokoyama, S., Hara, A., & Aoyama, T. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.04.011 · Cited by 43
Fibrate treatment for primary biliary cirrhosis
Cuperus, F. J. C., Halilbasic, E., & Trauner, M. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000056 · Cited by 36
Guoyun, X., Dawei, D., Ning, L., Yinan, H., Fangfang, Y., Siyuan, T., Hao, S., Jiaqi, Y., Ang, X., Guanya, G., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.948362 · Cited by 13
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis
Caines, A., Trudeau, S., & Gordon, S. C. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2390120 · Cited by 7
Metadata
- Authors
- KOK, T., BLOKS, V. W., WOLTERS, H., HAVINGA, R., JANSEN, P. L. M., STAELS, B., & KUIPERS, F.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2003-02-01
- Volume
- 369
- Issue
- 3
- Pages
- 539-547
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W2052516365
- Cited by
- 160
- References
- 4
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.